NUVATION BIO INC.

(NUVB)
  Report
Delayed Nyse  -  04:00 2022-08-08 pm EDT
2.640 USD   +6.02%
08/04NUVATION BIO : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)
PU
08/04NUVATION BIO : Reports Second Quarter 2022 Financial Results and Provides Business Update - Form 8-K
PU
08/04Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
BU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
08/02/2022 08/03/2022 08/04/2022 08/05/2022 08/08/2022 Date
2.29(c) 2.31(c) 2.37(c) 2.49(c) 2.64(c) Last
1 156 081 4 708 219 1 578 328 1 522 008 2 194 500 Volume
-8.03% +0.87% +2.60% +5.06% +6.02% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -117 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,83x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -138 M - -
Net Debt 2023 - - -
P/E ratio 2023 -4,63x
Yield 2023 -
Capitalization 576 M 576 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 85
Free-Float 71,9%
More Financials
Company
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing differentiated and novel therapeutic candidates focused on treating patients with cancer. The Company is advancing six wholly owned compounds that have resulted from drug discovery and development programs, which include NUV-422 a cyclin-dependent kinase (CDK) inhibitor, NUV-868 a bromodomain and extra terminal... 
More about the company
Ratings of Nuvation Bio Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C
More Ratings
All news about NUVATION BIO INC.
08/04NUVATION BIO : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)
PU
08/04NUVATION BIO : Reports Second Quarter 2022 Financial Results and Provides Business Update ..
PU
08/04Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
BU
08/04Nuvation Bio Inc. Reports Earnings Results for the Second Quarter and Six Months Ended ..
CI
08/02BTIG Downgrades Nuvation Bio to Neutral From Buy
MT
08/02BMO Capital Lowers Nuvation Bio to Market Perform From Outperform, Price Target to $2.5..
MT
08/01SECTOR UPDATE : Health Care Stocks Still Struggling Ahead of Market Close Monday
MT
08/01Wedbush Adjusts Price Target for Nuvation Bio to $5 From $17 on Discontinuation of NUV-..
MT
08/01Nuvation Bio to Discontinue Clinical Study of NUV-422 in Solid Tumors Following Clinica..
MT
08/01SECTOR UPDATE : Health Care Stocks Retreat Fractionally in Early Afternoon Trading
MT
08/01Nuvation Bio to Discontinue Clinical Study of NUV-422 in Solid Tumors Following Clinica..
MT
08/01NUVATION BIO : Announces Discontinuation of NUV-422 Clinical Development Program - Form 8-..
PU
08/01Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program
BU
08/01Nuvation Bio Inc. Announces Discontinuation of NUV-422 Clinical Development Program
CI
07/18Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentwo..
BU
More news
News in other languages on NUVATION BIO INC.
08/04Nuvation Bio Inc. annonce ses résultats pour le deuxième trimestre et les six mois term..
08/01MISE À JOUR SECTORIELLE : Les actions du secteur de la santé sont toujours en difficulté a..
08/01Nuvation Bio va interrompre l'étude clinique du NUV-422 dans les tumeurs solides suite ..
08/01MISE À JOUR SECTORIELLE : Les actions du secteur de la santé reculent de façon fractionnée..
08/01Nuvation Bio va interrompre l'étude clinique du NUV-422 dans les tumeurs solides suite ..
More news
Analyst Recommendations on NUVATION BIO INC.
More recommendations
Chart NUVATION BIO INC.
Duration : Period :
Nuvation Bio Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NUVATION BIO INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 2,64 $
Average target price 6,50 $
Spread / Average Target 146%
EPS Revisions
Managers and Directors
David T. Hung President, CEO & Director
Jennifer Fox Chief Financial Officer
Daniel G. Welch Chairman
Gary Hattersley Chief Scientific Officer
Dong Fang Liu Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NUVATION BIO INC.-70.71%543
MODERNA, INC.-26.44%73 092
IQVIA HOLDINGS INC.-16.80%43 781
LONZA GROUP AG-26.44%43 083
SEAGEN INC.13.72%32 426
ALNYLAM PHARMACEUTICALS, INC.28.89%26 235